中国寄生虫学与寄生虫病杂志 ›› 2010, Vol. 28 ›› Issue (3): 13-225.

• 综述 • 上一篇    下一篇

近年来发展抗血吸虫新药的进展

肖树华   

  1. 中国疾病预防控制中心寄生虫病预防控制所,卫生部寄生虫病原与媒介生物学重点实验室,世界卫生组织疟疾、血吸虫病和丝虫病合作中心,上海 200025
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2010-06-30 发布日期:2010-06-30

Progress in Development of New AntischistosomalDrugs in Recent Years

XIAO Shu-hua   

  1. National Institute of Parasitic Diseases,Chinese Center for Disease Control and Prevention;Key Laboratory of Parasite and Vector Biology,MOH;WHO collaborating Center for Malaria,Schistosomiasis and Filariasis,Shanghai 200025,China
  • Received:1900-01-01 Revised:1900-01-01 Online:2010-06-30 Published:2010-06-30

摘要: 【提要】 全球有2亿人感染血吸虫,其治疗仅依赖吡喹酮一种药物是很不相适应的。吡喹酮虽有很好的治疗效果,但无预防作用,故发展抗血吸虫新药倍受关注。本文综述近年来报道的恶二唑-2-氧化物和甲氟喹等抗血吸虫新药的实验研究,阐述这些药物的发展过程,及其抗血吸虫特点。

关键词: 血吸虫, 血吸虫病, 恶二唑-2-氧化物, 甲氟喹, 吡喹酮

Abstract: 【Abstract】 It is estimated that 200 million people have suffered the infection with schistosomes in the world. The fact that treatment of schistosomiasis only relies on a single drug praziquantel does not adapt to the demand. Although praziquantel exhibits excellent therapeutic efficacy, it shows no preventive action to the infection. Therefore, development of new anti-schistsomal drugs has been received serious attention. In this paper the recent development of new anti-schistosomal drugs such as oxadiazole-2-oxides, mefloquine, etc. has been reviewed, and the process of their development and anti-schistosomal properties recounted.

Key words: Schistosome, Schistosomiasis, Oxadizole-2-oxides, Mefloquine, Praziquantel